Ridker et al. illustrated that canakinumab confers a cardioprotective effect against atherosclerosis in patients with incident lung cancer by reducing the NLRP3 inflammasome, which subsequently inhibits the downstream signaling pathway of IL-1β. This evidence concerns the gene NLRP3 and lung carcinoma.